HRP20040077A2 - Crystalline forms vi and vii of atorvastatin-calcium - Google Patents
Crystalline forms vi and vii of atorvastatin-calciumInfo
- Publication number
- HRP20040077A2 HRP20040077A2 HR20040077A HRP20040077A HRP20040077A2 HR P20040077 A2 HRP20040077 A2 HR P20040077A2 HR 20040077 A HR20040077 A HR 20040077A HR P20040077 A HRP20040077 A HR P20040077A HR P20040077 A2 HRP20040077 A2 HR P20040077A2
- Authority
- HR
- Croatia
- Prior art keywords
- atorvastatin
- vii
- calcium
- crystalline forms
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN620MA2001 | 2001-07-30 | ||
| PCT/US2002/000431 WO2003011826A1 (en) | 2001-07-30 | 2002-01-07 | Crystalline forms vi and vii of atorvastatin calcium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20040077A2 true HRP20040077A2 (en) | 2004-06-30 |
Family
ID=35160889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20040077A HRP20040077A2 (en) | 2001-07-30 | 2002-01-07 | Crystalline forms vi and vii of atorvastatin-calcium |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP2292600A1 (cs) |
| JP (1) | JP2005500351A (cs) |
| KR (1) | KR20040019043A (cs) |
| CN (1) | CN100471836C (cs) |
| AU (1) | AU2002255479B2 (cs) |
| BG (1) | BG108518A (cs) |
| BR (1) | BR0211488A (cs) |
| CA (1) | CA2454500C (cs) |
| CZ (1) | CZ2004126A3 (cs) |
| EE (1) | EE200400048A (cs) |
| HR (1) | HRP20040077A2 (cs) |
| IL (2) | IL159626A0 (cs) |
| MX (1) | MXPA04000889A (cs) |
| NO (1) | NO20040390L (cs) |
| NZ (1) | NZ530785A (cs) |
| PL (1) | PL368647A1 (cs) |
| RU (1) | RU2304139C2 (cs) |
| WO (1) | WO2003011826A1 (cs) |
| ZA (1) | ZA200400573B (cs) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| JP2004513956A (ja) * | 2000-11-03 | 2004-05-13 | テバ ファーマシューティカル インダストリーズ リミティド | アトルバスタチンヘミカルシウムvii型 |
| US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| CZ20032019A3 (cs) * | 2000-12-27 | 2003-10-15 | Ciba Specialty Chemicals Holding Inc. | Krystalické formy Atorvastatinu |
| WO2003070702A1 (en) * | 2002-02-15 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
| US7122681B2 (en) | 2002-02-19 | 2006-10-17 | Teva Pharmaceutical Industries, Ltd. | Desolvation process for the production of atorvastatin hemi-calcium essentially free of bound organic solvent |
| WO2004050618A2 (en) * | 2002-11-28 | 2004-06-17 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
| EP1424324A1 (en) * | 2002-11-28 | 2004-06-02 | Teva Pharmaceutical Industries Limited | Crystalline form F of Atorvastatin hemi-calcium salt |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| ATE545629T1 (de) | 2004-03-17 | 2012-03-15 | Ranbaxy Lab Ltd | Verfahren zur herstellung von atorvastatin- calcium in amorpher form |
| CA2560282A1 (en) * | 2004-03-17 | 2005-09-29 | Ranbaxy Laboratories Limited | Crystalline form of atorvastatin hemi calcium |
| CA2573969C (en) | 2004-07-16 | 2014-02-04 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
| BRPI0513422A (pt) * | 2004-07-20 | 2008-05-06 | Warner Lambert Co | formas de sais cálcio do ácido (r-(r*))-2-(4- fluorfenil)-(beta), (sigma)-diidróxi-5-(1-metiletil) -3-fenil-4-((fenilamino) carbonil)-1h-pirrol-1-heptanóico (2:1) |
| TWI321132B (en) * | 2004-09-28 | 2010-03-01 | Teva Pharma | Process for preparing forms of atorvastatin calcium substantially free of impurities |
| NZ554541A (en) | 2004-10-28 | 2011-01-28 | Warner Lambert Co | Process for forming amorphous atorvastatin |
| WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
| CA2633268A1 (en) * | 2005-12-13 | 2007-06-21 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| EP2185527A2 (en) * | 2007-07-11 | 2010-05-19 | Actavis Group PTC EHF | Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium |
| KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
| CN104983702A (zh) * | 2015-07-23 | 2015-10-21 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂 |
| CN108157405B (zh) * | 2018-02-06 | 2020-10-02 | 上海应用技术大学 | 一种灭蟑螂饵剂及其制备方法和应用 |
| WO2025147589A1 (en) | 2024-01-05 | 2025-07-10 | Osanni Bio, Inc. | Implants, compositions, and methods for treating retinal diseases and disorders |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
| US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| IL109570A0 (en) * | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
| IL128862A (en) * | 1995-07-17 | 2007-12-03 | Warner Lambert Co | [R - (R * R *)] - 2 - (4 - fluorophenyl) - ß, d - dihydroxy - 5 - (1 - methyl - ethyl) 3 - phenyl - 4 - [(phenamino) carbonyl)] - 1H - Pyrol - 1 - Patenoic acid Hydrogen salt Hydrogen crystalline (Atorostatin) Crystalline hydrate |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| US6087511A (en) | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| US5929156A (en) | 1997-05-02 | 1999-07-27 | J.M. Huber Corporation | Silica product for use in elastomers |
| HU226640B1 (en) | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
| ES2234699T3 (es) * | 1999-11-17 | 2005-07-01 | Teva Pharmaceutical Industries Ltd. | Forma polimorfica de atorvastatina calcio. |
| JP2004513956A (ja) * | 2000-11-03 | 2004-05-13 | テバ ファーマシューティカル インダストリーズ リミティド | アトルバスタチンヘミカルシウムvii型 |
| CA2427255A1 (en) * | 2000-11-16 | 2002-06-06 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| CZ20032019A3 (cs) * | 2000-12-27 | 2003-10-15 | Ciba Specialty Chemicals Holding Inc. | Krystalické formy Atorvastatinu |
| WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
-
2002
- 2002-01-07 MX MXPA04000889A patent/MXPA04000889A/es active IP Right Grant
- 2002-01-07 RU RU2004103470/04A patent/RU2304139C2/ru not_active IP Right Cessation
- 2002-01-07 CZ CZ2004126A patent/CZ2004126A3/cs unknown
- 2002-01-07 CN CNB028150708A patent/CN100471836C/zh not_active Expired - Fee Related
- 2002-01-07 EE EEP200400048A patent/EE200400048A/xx unknown
- 2002-01-07 WO PCT/US2002/000431 patent/WO2003011826A1/en not_active Ceased
- 2002-01-07 CA CA002454500A patent/CA2454500C/en not_active Expired - Fee Related
- 2002-01-07 HR HR20040077A patent/HRP20040077A2/xx not_active Application Discontinuation
- 2002-01-07 EP EP10010845A patent/EP2292600A1/en not_active Withdrawn
- 2002-01-07 AU AU2002255479A patent/AU2002255479B2/en not_active Ceased
- 2002-01-07 NZ NZ530785A patent/NZ530785A/en not_active IP Right Cessation
- 2002-01-07 BR BR0211488-7A patent/BR0211488A/pt not_active Application Discontinuation
- 2002-01-07 EP EP02724877A patent/EP1414796A1/en not_active Withdrawn
- 2002-01-07 PL PL02368647A patent/PL368647A1/xx unknown
- 2002-01-07 KR KR10-2004-7000093A patent/KR20040019043A/ko not_active Ceased
- 2002-01-07 IL IL15962602A patent/IL159626A0/xx unknown
- 2002-01-07 JP JP2003517018A patent/JP2005500351A/ja active Pending
-
2003
- 2003-12-29 IL IL159626A patent/IL159626A/en not_active IP Right Cessation
-
2004
- 2004-01-09 BG BG108518A patent/BG108518A/xx unknown
- 2004-01-26 ZA ZA200400573A patent/ZA200400573B/en unknown
- 2004-01-29 NO NO20040390A patent/NO20040390L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL368647A1 (en) | 2005-04-04 |
| CN1537098A (zh) | 2004-10-13 |
| EP2292600A1 (en) | 2011-03-09 |
| CZ2004126A3 (cs) | 2004-12-15 |
| CN100471836C (zh) | 2009-03-25 |
| EE200400048A (et) | 2004-04-15 |
| RU2304139C2 (ru) | 2007-08-10 |
| IL159626A0 (en) | 2004-06-01 |
| WO2003011826A1 (en) | 2003-02-13 |
| KR20040019043A (ko) | 2004-03-04 |
| CA2454500C (en) | 2009-11-10 |
| RU2004103470A (ru) | 2005-06-20 |
| MXPA04000889A (es) | 2004-06-03 |
| EP1414796A1 (en) | 2004-05-06 |
| NO20040390L (no) | 2004-01-29 |
| IL159626A (en) | 2013-04-30 |
| CA2454500A1 (en) | 2003-02-13 |
| AU2002255479B2 (en) | 2008-09-11 |
| JP2005500351A (ja) | 2005-01-06 |
| NZ530785A (en) | 2005-10-28 |
| BG108518A (en) | 2004-08-31 |
| ZA200400573B (en) | 2005-05-11 |
| BR0211488A (pt) | 2004-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20040077A2 (en) | Crystalline forms vi and vii of atorvastatin-calcium | |
| TW479494U (en) | Structure of pillow | |
| AU2002362061A8 (en) | Preparation of orlistat and orlistat crystalline forms | |
| HUP0402536A3 (en) | Novel crystalline forms of meloxicam and the preparation and interconversion methods thereof | |
| EP1430054A4 (en) | PURIFICATION AND CRYSTALLINE FORMS OF ZALEPLON | |
| IL159266A0 (en) | Crystalline forms of fexofenadine and processes for the preparation thereof | |
| HUP0500734A3 (en) | Use of 2-alkoxyphenyl-substituted imidazotriazinones | |
| GB0115581D0 (en) | Method of mass spectometry | |
| IL161178A0 (en) | MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES | |
| IL161608A0 (en) | Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines | |
| AU2002322445A1 (en) | Crystals and structures of arnb aminotransferases | |
| AU2002357159A8 (en) | Manufacture of trialkylaluminum compounds and alpha-alcohols | |
| TW493498U (en) | Structure improvement of screwdriver | |
| TW493722U (en) | Improved structure of lampwick | |
| EP1414427A4 (en) | KAVALACTONE COMPOSITIONS AND METHODS OF USE | |
| IL157243A0 (en) | Preparation of n-methylparoxetine and related intermediate compounds | |
| EP1392460A4 (en) | AMINOSILANOL HYDROFLUORIDES AND THEIR USE | |
| GB0130452D0 (en) | Antifouling prodct and method of making it | |
| TW484490U (en) | Structural improvement of multiple-functional wrench | |
| HU0104370D0 (en) | Honeyed schnaps of oerseg | |
| SI1448564T1 (sl) | Substituirane indolizinu podobne spojine in postopki uporabe | |
| GB0127380D0 (en) | Formation of small crystals | |
| GB0111083D0 (en) | Formation of small crystals | |
| TW493490U (en) | Improved structure of wrench | |
| TW484488U (en) | Improved structure of quick-withdrawn wrench |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| OBST | Application withdrawn |